中国中药杂志

1998, (10) 3-5

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

银杏叶提取物血液流变学研究
Effects of the Leaf of Ginkgo biloba L. Extract on Blood Rheology in Animals

沈连忠,崔艳英,王淑仙
Shen Lianzhong and Cui Yanying (Beijing Municipal Institute for Drug Control,Beijing 100035) Wang Shuxian(Department for New Drug Funds,State Pharmaceutical Administration of China,Beijing 100035)

摘要(Abstract):

目的:观察银杏叶提取物对动物血液粘弹性、血液凝固过程以及血小板聚集功能的影响。方法:体外给药,测定全血的血液粘弹性;分离血小板,测定高、低浓度的ADP诱导的血小板聚集的半数抑制浓度;小鼠iv给药,测定给药后血液凝固过程。结果:体外可明显延长大鼠的复钙时间,减缓血液粘、弹性的增加速率,降低血液的最大粘、弹性;小鼠iv100,200mg/kg明显延长血液凝固时间,对血液纤维网的形成以及血凝块的退缩均有明显抑制作用;体外能抑制高、低浓度ADP诱导的血小板聚集,并对低浓度ADP诱导的血小板聚集有促进解聚作用。结论:银杏叶提取物具有降低血液粘弹性,延缓血液凝固和抑制血小板聚集功能的作用
Objective:To observe the effects of the leaf of Ginkgo biloba extract(GBE)on viscosity and elasticity,coagulation of blood and aggregation of blood platelets.Method:The viscosity and elasticity of the whole blood in rats was determined using an in vitro method.The half inhibitory concentration of the drug inhibiting rabbit platelet aggregation was also determined using ADP as an inducer. The blood coagulation in mice was recorded with a coagulation analyser after GBE was administrated by vein injection.Result:GBE significantly lengthened the recalcium time,lowered the increase ratios of viscosity and elasticity,and reduced the maximum viscosity and elasticity.At doses of 100 and 200mg/kg administrated by vein injection GBE lengthened the coagulation time,reduced the fibriogenesis and clot retraction ratio significantly in mice.GBE can also inhibit rabbit platelet aggregation induced by ADP and promote the disband of the aggregated platelets.Conclusion:GBE is helpful in reducing viscosity and elasticity of the whole blood,slowing blood coagulation and inhibiting platelet aggregation.

关键词(KeyWords): 银杏叶提取物,血液粘弹性,血液凝固分析,血小板聚集
the leaf of Ginkgo biloba extract;blood rheology;blood coagulation;platelet aggregation

Abstract:

Keywords:

基金项目(Foundation): 国家医药管理局新药基金

作者(Author): 沈连忠,崔艳英,王淑仙
Shen Lianzhong and Cui Yanying (Beijing Municipal Institute for Drug Control,Beijing 100035) Wang Shuxian(Department for New Drug Funds,State Pharmaceutical Administration of China,Beijing 100035)

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享